Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by TriSalus Life Sciences, Inc. on May 14, 2026. The filing details the voting results for director elections, auditor ratification, and executive compensation proposals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
A total of 41,728,676 shares (67.9% of outstanding shares) were represented at the meeting. Key outcomes include:
- Director Elections: Mary Szela and Gary Gordon were elected to three-year terms expiring in 2029. Both nominees received over 31 million "For" votes.
- Auditor Ratification: Grant Thornton, LLP was ratified as the independent registered accounting firm for the fiscal year ending December 31, 2026.
- Compensation Frequency: Stockholders approved conducting future advisory votes on executive compensation every three years.
- Executive Compensation: The advisory proposal to approve named executive officer compensation was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Investor Verification Checklist
- Verify the final share count and percentage of attendance (67.9%) against the company's latest 10-K or 10-Q.
- Confirm the appointment of Grant Thornton, LLP as the independent auditor for fiscal year 2026.
- Review the specific compensation details for named executive officers referenced in the advisory vote.
- Check the Board of Directors' composition to confirm the new three-year terms for Mary Szela and Gary Gordon.